<DOC>
	<DOCNO>NCT01529268</DOCNO>
	<brief_summary>CyNCh multi-center , placebo-controlled clinical trial child age 8 17 year biopsy-confirmed moderate severe nonalcoholic fatty liver disease ( NAFLD ) . The primary objective evaluate whether 52 week treatment cysteamine bitartrate delayed-release capsule result improvement liver disease severity .</brief_summary>
	<brief_title>Cysteamine Bitartrate Delayed-Release Treatment NAFLD Children</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>Children age 817 year Liver biopsy obtain within 90 day screen visit 120 day randomization Clinical history consistent NAFLD Definite NAFLD base upon liver histology No evidence liver disease clinical history histological evaluation A histological severity : NAFLD Activity Score ( NAS ) â‰¥ 4 . Sexually active female participant childbearing potential ( i.e. , surgically sterile [ define tubal ligation , hysterectomy , bilateral oophorectomy ] ) must agree utilize two acceptable form contraception screen completion study complete serum pregnancy test study visit . The acceptable form contraception study include hormonal contraceptive ( oral , implant , transdermal patch , injection ) stable dose least 3 month prior screen , barrier ( condom spermicide , diaphragm spermicide ) . Sexual activity ascertain study visit postmenarchal female sexually active , subject must verify use 2 acceptable form contraception . For prepubescent child , document attestation abstinence parent guardian acceptable . Participants must able swallow DR Cysteamine tablet tablet intact Written inform consent parent legal guardian Written inform assent child There exclusion criterion base race , ethnicity gender . Participants current history follow condition health issue make unsafe participate opinion Investigators : Inflammatory bowel disease ( currently active ) prior resection small intestine Heart disease ( e.g. , myocardial infarction , heart failure , unstable arrhythmia ) Seizure disorder Active coagulopathy Gastrointestinal ulcers/bleeding Renal dysfunction creatinine clearance &lt; 90 mL/min/m2 History active malignant disease require chemotherapy within past 12 month prior randomization History significant alcohol intake ( AUDIT questionnaire ) inability quantify alcohol consumption Chronic use ( 2 consecutive week ) medication know cause hepatic steatosis steatohepatitis ( systemic glucocorticoid , tetracycline , anabolic steroid , valproic acid , salicylate , tamoxifen ) past year . The use know hepatotoxin within 90 day liver biopsy within 120 day randomization Initiation medication intent treat NAFLD/NASH time period follow liver biopsy prior randomization History total parenteral nutrition ( TPN ) use year prior screen History bariatric surgery planning undergo bariatric surgery study duration Clinically significant depression ( patient hospitalize suicidal ideation suicide attempt within past 12 month ) Any female nursing , plan pregnancy , know suspected pregnant , positive serum pregnancy screen . Noncompensated liver disease one follow hematologic , biochemical , serological criterion entry protocol : Hemoglobin &lt; 10 g/dL ; White blood cell ( WBC ) &lt; 3,500 cells/mm3 blood ; Neutrophil count &lt; 1,500 cells/mm3 blood ; Platelets &lt; 130,000 cells/mm3 blood ; Direct bilirubin &gt; 1.0 mg/dL Total bilirubin &gt; 3 mg/dL Albumin &lt; 3.2 g/dL International normalized ratio ( INR ) &gt; 1.4 Poorly control diabetes mellitus ( hemoglobin A1c ( HbA1c ) &gt; 9 % ) Evidence chronic liver disease : Biopsy consistent histological evidence autoimmune hepatitis Serum hepatitis B surface antigen ( HBsAg ) positive . Serum hepatitis C antibody ( antiHCV ) positive . Iron/total iron binding capacity ( TIBC ) ratio ( transferrin saturation ) &gt; 45 % histological evidence iron overload Alpha1antitrypsin ( A1AT ) phenotype ZZ SZ Wilson 's disease Children currently enrol clinical trial receive investigational study drug within 180 day screen liver biopsy . Subjects able willing comply protocol condition would impede compliance hinder completion study , opinion investigator . Failure give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Nonalcoholic Fatty Liver Disease ( NAFLD )</keyword>
	<keyword>Cysteamine bitartrate delay release</keyword>
	<keyword>Children</keyword>
</DOC>